Fosun Pharma

Fosun Pharma to pay $240 million for Alma Lasers

Fosun Pharma and Pramerica-Fosun China Opportunity Fund intend to buy a leading Israeli aesthetic medical devices manufacturer.
<div style="text-align: left;"> Alma Lasers is a global developer, manufacturer and provider of lasers for aesthetic and medical applications </div>
<div style="text-align: left;"> Alma Lasers is a global developer, manufacturer and provider of lasers for aesthetic and medical applications </div>
April 29, 2013

Shanghai Fosun Pharma, the subsidiary of Fosun International, and Pramerica-Fosun China Opportunity Fund will pay $240 million for up to 95.6% of Israel-based Alma Lasers.

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media